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Objectives: Surgical resection is the standard treatment for stage II non–small cell
lung cancer, but recurrence rates approach 60%. This study compared mutational
changes in involved lymph nodes and primary tumors from patients with stage II
non–small cell lung cancer to determine whether risk factors for recurrence could be
identified.
Methods: Forty patients with resected stage II non–small cell lung cancer (excluding
T3 N0 disease) were studied. Microdissection was performed on primary tumors and
lymph nodes. Analysis was performed across 9 genomic loci by using polymerase
chain reaction amplification. The ratio of fractional allelic loss between involved
lymph nodes and primary tumors was used to stratify patients into high-risk
(fractional allelic loss ratio of 1) and low-risk (fractional allelic loss ratio of 1)
groups.
Results: The median age of the patients was 68 years (range, 42-85 years). Median
follow-up was 30 months. Fractional allelic loss was greater in patients with
squamous carcinomas compared with that in adenocarcinomas, but survival was
similar (35 vs 39 months). The median survival was 35 months in high-risk patients
and was not reached in low-risk patients (P  .3). Disease-free survival was 24
months in high-risk patients and was not reached in low-risk patients (P  .35). In
the subset with adenocarcinoma (n  18), median survival was 24 months in the
high-risk group; no deaths occurred in low-risk patients (P  .01). Also, disease-
free survival was 14 months in high-risk patients and was not reached in the low-risk
patients (P  .05).
Conclusions: Squamous cancers demonstrate greater mutational changes than ade-
nocarcinomas; this does not affect outcome. The patients with low-risk adenocar-
cinomas demonstrated superior outcomes compared with those of other patients.
These results should be confirmed in larger studies.
The current standard of care for stage II non–small cell lung cancer(NSCLC) is pulmonary resection. However, overall survival for thispatient group is less than 40%.1 Adjuvant therapy, using radiation orchemotherapy trials, has generally failed to demonstrate any im-provement in survival for this subset of NSCLC over the benefits ofsurgical intervention alone.2,3 Although providing some insight into
the prognosis and guidelines for therapy, the staging system currently in place is
From the Division of Thoracic and Foregut
Surgery,a the Department of Pathology,b
and the Department of Dental Public
Health,c University of Pittsburgh Medical
Center Health System, UPMC Presbyte-
rian, Pittsburgh, Pa.
Read at the Eighty-second Annual Meeting
of The American Association for Thoracic
Surgery, Washington, DC, May 5-8, 2002.
Received for publication May 10, 2002;
revisions requested Sept 10, 2002; revisions
received Nov 30, 2002; accepted for publi-
cation Feb 3, 2003.
Address for reprints: Hiran C. Fernando,
FRCS, Division Thoracic Surgery, UPMC
Presbyterian, 200 Lothrop St, Suite C-800,
Pittsburgh, PA 15213 (E-mail:
fernandohc@msx.upmc.edu).
J Thorac Cardiovasc Surg 2004;127:87-91
0022-5223/$30.00
Copyright © 2004 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2003.02.001
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 1 87
G
TS
inadequate. Molecular studies of NSCLC have been a sub-
ject of significant interest in the recent literature. One ap-
proach has been to study the effect of a single gene on
outcomes after treatment for NSCLC. However, several
molecular events are known to be associated with the pro-
gression of NSCLC, and it is unlikely that a single genetic
aberration by itself will account for the clinical behavior of
a cancer. Allelic loss, which is one of the common genetic
events involved in tumorigenesis and progression, is accu-
mulated throughout the process of tumor evolution.4,5
This study was designed to analyze allelic loss (and
therefore mutational change) in primary tumors and histo-
logically positive N1 lymph nodes in patients with stage II
lung cancer who had undergone pulmonary resection. We
selected patients with stage II NSCLC (on the basis of N1
disease) because these patients are usually treated with
surgical intervention alone but still have a high incidence of
recurrent disease. Because this patient group is character-
ized by involvement of N1 lymph nodes, we believed that
allelic loss within the lymph nodes would play an important
role in determining survival. We hypothesized that those
patients with more severe mutational changes in lymph
nodes would be expected to have poorer outcomes.
Materials and Methods
The archived paraffin blocks of 40 patients with stage II NSCLC
were studied after obtaining institutional review board approval.
All patients had stage II disease on the basis of pathologically
involved N1 lymph nodes. We excluded patients with T3N0 tu-
mors. Additional inclusion criteria were the presence of adenocar-
cinoma or squamous carcinoma only. All patients underwent a
standard pulmonary resection (lobectomy or pneumonectomy). We
excluded patients who had limited resections, such as a wedge or
segmental resection.
A minimum of 2 sites within the primary tumor and 1 involved
NI lymph node were studied. The most anaplastic areas, as as-
sessed on light microscopy, were selected for microdissection. In
the lymph nodes cancer cells are cohesive and tend to form nodular
aggregates, and therefore it was relatively easy for the pathologists
to microdissect pure metastatic tumor. In the case of primary
tumor, cancer cell nests could occasionally be embedded in fibrous
tissue or admixed with inflammatory cells, and therefore it was
possible that pure tumor was not obtained. However, because the
primary tumor was usually large enough, it was possible to avoid
these areas, with the purity of all microdissected specimens esti-
mated to be greater than 90%. Additionally, an area of normal
parenchyma was also studied to serve as an internal control and to
assess for allelic dropout.6 Microdissection was performed at all
these sites, obtaining 4-m-thickness and 2- to 6-mm- diameter
sections of tissue by using methods previously described.7
After digestion of the microdissected tissue with proteinase K,
aliquots of sampled tissue were used in individual polymerase
chain reaction amplification reactions targeting microsatellites sit-
uated in proximity to genes of interest. The 16-microsatellite
markers chosen were located on 9 chromosomal loci (CLs). These
loci are situated within or adjacent to 9 known tumor suppressor
genes or oncogenes potentially involved in lung carcinogenesis.
The relationship of microsatellite to CLs and genes are indicated in
Table 1. The use of more than one microsatellite marker provided
a higher yield of information for each CL.
Loss of Heterozygosity Analysis
Determination of allelic loss was carried out by using phosphorous
33 autoradiography, as previously described.7 Allelic dropout was
evaluated by imposing a requirement that all normal lung samples
must show equal band intensity for the microsatellite being tested
on autoradiography. Any patient not showing this was rejected for
assessment of allelic loss. Therefore if, in a hypothetic case, the
normal lung demonstrated equal band intensity in 8 of the 9 CLs,
then 8 CLs were informative.
Loss of heterozygosity (LOH) was determined for both the tumor
and lymph node metastases. If there was a diminished band intensity
of at least one half the other corresponding bands for CLs that were
informative, then LOH was demonstrated. Analysis of microsatellites
provided increased information about each CL. As long as LOH was
demonstrated in one of the microsatellites related to a particular CL,
then that CL was classified as demonstrating LOH. Additionally, as
described above, at least 2 primary tumor sites and 1 lymph node site
were microdissected for each patient. In some cases heterogeneity was
observed in these different sampled sites. If LOH was present in at
least one of the microdissected sites, then LOH was recorded as being
present for the node or tumor being examined. Two observers eval-
uated LOH independently for each specimen, with a concordance
ratio of positive LOH of 100%.
Fractional Allelic Loss and Determination of Risk
Group
Determination of the LOH and informative rate allowed calcula-
tion of the fractional allelic loss (FAL). This was defined as the
LOH of the tumor or node divided by the number of informative
CLs in the associated normal lung. By using the same hypothetic
case described above as an example, if analysis of a primary tumor
demonstrates LOH in 4 CLs, and analysis of the node demonstrates
LOH in 2 CLs, then the FAL for the primary tumor is 0.5 (ie, 4/8),
and the node is 0.25 (ie, 2/8).
Stratification into risk groups was then made by dividing the
FAL in the node by the FAL in the tumor. Because a ratio of 1 or
more indicated mutational damage that was as severe or worse in
TABLE 1. Relationships of microsatellite, chromosomal lo-
cus, and gene
Microsatellite
Chromosomal
locus Gene
D1S407, MYCL1 1p34 L-myc
D3S1539, D3S2303 3p26 OGG1
D5S592, D5S615,
MCC.E10
5q21 APC
D7S1530 7q31 c-MET
D8S373 8p24 c-myc
D9S254, D9S251 9p21 p16
D10S1173, D10S520 10q23 PTEN
D17S1163, TP53 17p13 p53
D18S814 18q21 DCC
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the nodal metastasis, these patients were classified as high risk. All
other patients were classified as low risk. For our hypothetic case,
the FAL ratio would be 0.5 (ie, low risk).
Statistical Analysis
All data were entered into an SPSS (version 10.0 for Windows)
file. Statistical analysis included t-test analysis of mean values and
Kaplan-Meier survival analysis with Breslow tests to compare
groups.
Results
The forty patients included 28 men and 12 women. The
median age was 68 years (range, 42-85 years). The opera-
tions were performed over a 4-year period from 1994 to
1998. The operations performed included 26 lobectomies
and 14 pneumonectomies. Final histologies were squamous
carcinoma in 22 patients and adenocarcinoma in 18 patients,
with 8 stage IIa and 32 stage IIb tumors. Median follow-up
was 30 months (range, 1-81 months).
The informativeness and frequency of LOH of each
microsatellite are shown in Table 2. Informativeness ranged
from as low as 48% to as high as 95%. The mean FALs for
the tumor and nodal metastases are demonstrated in Table 3.
Mean FAL in both tumor and nodal tissue was significantly
higher for squamous cancers than for adenocarcinomas.
However, median survival for squamous carcinomas and
adenocarcinomas were similar at 35 and 39 months, respec-
tively (P  .65). Median survivals were also similar for
stage IIa versus IIb disease (38 vs 39 months, P  .96) and
for patients who underwent lobectomy compared with pneu-
monectomy (30 months for lobectomy; median survival was
not reached for pneumonectomy; P  .84).
There were 20 high-risk patients and 20 low-risk pa-
tients. Median survival was not reached in the low-risk
patients and was 35 months for the high-risk patients. This
was not significantly different (P .3). Median disease-free
survival (DFS) was not reached in low-risk patients and was
24 months in high-risk patients. This was not significantly
different (P  .36)
When looking at the adenocarcinomas and squamous
carcinomas separately, we found that 9 (41%) of 22 of the
squamous carcinomas and 11 (61%) of 18 of the adenocar-
cinomas were in high-risk patients. Survival and DFS were
not significantly different for low-risk and high-risk squa-
mous cell cancers (Figures 1 and 2). Analysis of the patients
with adenocarcinoma revealed significant differences be-
tween low-risk and high-risk tumors. These are shown in
Figures 3 and 4. There were no deaths in the low-risk
patients with adenocarcinoma compared with a median sur-
vival of 25 months in the high-risk patients with adenocar-
cinoma (P  .01). The median DFS was not reached for the
low-risk patients with adenocarcinoma compared with 14
months for the high-risk patients (P  .05).
TABLE 3. Fractional allele loss in adenocarcinoma and
squamous carcinoma
FAL in primary
tumor
FAL in node
metastasis
Squamous carcinoma
(n  22)
0.7 0.63
Adenocarcinoma
(n  18)
0.41 0.31
Significance
(squamous
carcinoma vs
adenocarcinoma)
P  .01 P  .01
FAL, Fractional allele loss.
TABLE 2. Informative rate and overall frequency of LOH of each microsatellite
Chromosome
locus Microsatellite
Informative
rate (n)
LOH in primary
tumor (n)
LOH in lymph
node (n)
1p D1S407 70% (28/40) 43% (12/28) 41% (11/27)
MYCL1 78% (31/40) 58% (18/31) 45% (1/31)
3p D3S1539 78% (31/40) 61% (19/31) 52% (16/31)
D3S2303 80% (32/40) 66% (21/32) 52% (16/31)
5q D5S592 68% (27/40) 48% (13/27) 37% (10/27)
D5S615 80% (32/40) 56% (18/32) 45% (14/31)
MCC 48% (19/40) 47% (9/19) 47% (9/19)
7q D7S1530 63% (25/40) 48% (12/25) 36% (9/25)
8q D8S373 69% (27/39) 44% (12/27) 26% (7/27)
9p D9S254 65% (26/40) 69% (18/26) 58% (15/26)
D9S251 73% (29/40) 48% (14/29) 38% (11/29)
10q D10S1173 80% (32/40) 53% (17/32) 38% (12/32)
D10S520 58% (23/40) 83% (19/23) 65% (15/23)
17p D17S1163 95% (38/40) 30% (11/37) 32% (12/37)
TP53 58% (23/40) 74% (17/23) 65% (15/23)
18q D18S814 53% (21/40) 62% (13/21) 38% (8/21)
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Discussion
Stage II NSCLC is usually treated with surgical intervention
alone. However, the relatively low survival compared with that
seen in patients with stage I NSCLC and the high incidence of
systemic metastasis after recurrence8 suggest the need for
additional therapy. Adjuvant therapies have not met with suc-
cess.2,3 Prognostic markers that could successfully stratify pa-
tients might allow us to more effectively direct therapy.
Molecular staging techniques to assess prognosis are
usually performed for early stage disease, typically in pa-
tients with stage I disease.9 Patients with more advanced
tumors are considered to have a dismal prognosis, regard-
less of the status of the biologic marker investigated,10 and
have not been studied to the same degree. One approach in
early stage NSCLC has been to study histologically nega-
tive mediastinal lymph nodes for the presence of occult
micrometastatic disease.11 Another approach that has been
described is the use a panel of molecular markers to stratify
patients rather than a single-marker approach.10 In a study
of 408 patients with stage I NSCLC using 10 markers,
significant differences in survival were seen for those pa-
tients with 6 to 9 markers compared with that seen in those
with 0 to 3 markers present.10
We elected to use a panel approach in this study. Because
all these patients had histologically involved lymph nodes, we
hypothesized that the mutational changes in these lymph nodes
would allow us to predict biologic behavior. We have previ-
ously demonstrated that no single LOH in the primary tumor is
associated with prognosis in stage II NSCLC.12 However,
LOH at CLs 3p and 5q in the lymph node is associated with
decreased survival.12 This supports the view that the FAL of
lymph nodes plays an important role when N1 disease is present.
Previous studies have reported the higher frequency of loss
of chromosomal arms in squamous carcinomas compared with
Figure 2. DFS in patients with squamous cell carcinoma. Figure 4. DFS in patients with adenocarcinoma.
Figure 1. Survival in patients with squamous carcinomas. Figure 3. Survival in patients with adenocarcinoma.
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that in adenocarcinomas.13,14 Our data support these findings
of differences in the genetic profiles between adenocarcinomas
and squamous carcinomas. Squamous carcinomas had a higher
FAL in both lymph nodes and in primary tumors. However,
survival between squamous carcinomas and adnocarcinomas
was similar despite these genetic differences.
Our hypothesis was that if mutational changes were more
severe in the lymph nodes compared with in the primary tumor
(determined on the basis of the FAL ratio), this would predict
behavior. Although there was a trend for worse survival in
patients who had an FAL ratio of 1 or more, this was not
statistically significant. Further analysis revealed that the dif-
ferences lay within the adenocarcinoma group. When squa-
mous carcinomas were excluded, the difference between low-
risk and high-risk patients became statistically significant, with
no deaths in the low-risk adenocarcinoma group. Thus it ap-
pears that the patients with low-risk stage II adenocarcinomas
appear to be a subset with favorable outcomes.
The explanation for these differences is unclear. Perhaps
the greater LOH seen in squamous carcinomas overall makes
comparison between the lymph nodes and primary tumors less
meaningful. The behavior of adenocarcinoma appears to be
more variable and might depend on the pattern of LOH.
Although not studied here, the LOH profile in primary adeno-
carcinoma might predict outcomes in stage I tumors. By the
time N1 disease has occurred, the lymph node appears to be the
critical factor rather than the primary tumor.
In conclusion, we have demonstrated differences in LOH
between squamous carcinomas and adenocarcinomas. Both
survival and DFS were improved in low-risk stage II ade-
nocarcinomas on the basis of the FAL ratio between the
lymph node and the primary tumor. Larger studies will be
needed to confirm the findings of this pilot study.
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Discussion
Dr Steven J. Mentzer (Boston, Mass). If the cells that are in the
lymph node have an LOH and the mutation reflects the LOH observed
in different parts of the tumor, then isn’t it simply a selection issue?
In other words, couldn’t active selection within the node produce this
subset of the tumor found in the lymph node?
Dr Fernando. It might be true that we are seeing a subset of tumor
within the lymph node and that this might be a sampling issue. However,
in some cases we are seeing a different and more severe pattern of LOH
in the involved lymph node compared with in the primary tumor, which
is why we believe the node is important for predicting clinical behavior.
Dr David R. Jones (Charlottesville, Va). Did you look at the
histologic grade of the tumor? Is your analysis of mutational
alterations in the tumor any better than evaluating whether the
tumor is well differentiated, poorly differentiated, or moderately
differentiated?
Finally, which loci do you currently recommend analyzing? All 9?
Or were there 3 or 4 that you were able to identify as the main players
when you analyzed your LOH analysis?
Dr Fernando. There were 2 CLs in the lymph nodes that were
associated with poor prognosis. These were 3p and 5q. When we
looked at the primary tumor, we could not identify any CL that was
associated with prognosis.
Dr Steven J. Mentzer, (Boston, Mass). So you did not find any
evidence of active selection within the lymph node as opposed to
just passive embolic spread of the tumor? Was there anything that
would suggest to you that you had active selection; that is, that the
immune system was recognizing the tumor within the lymph node?
Dr Fernando. No, active selection within the lymph node was
not addressed in this study.
Dr S. Mentzer. Thank you very much.
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